Back-To-School Program
Help your patients prepare for the changes in asthma triggers that come with the return to school, and watch videos of thought leaders on this topic.
2007 NIH Asthma Guidelines
Watch Dr. William Busse discuss selected key changes in the 2007 update of the NIH asthma guidelines.
Office Visit Asthma Assessment
Watch this brief video
to learn the 3 key topics to discuss with asthma patients at every scheduled visit.
Attend an eMedical Forum
View more than a dozen different asthma presentations—live and interactive, or archived.
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older.
SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician.
Safety and effectiveness of SINGULAIR in patients younger than 12 months have not been established.
Patients should be advised to take SINGULAIR daily as prescribed, even when they are asymptomatic, as well as during periods of worsening asthma, and to contact their physician if their asthma is not well controlled.
Prescribing Information | Patient Product Information
This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico. SINGULAIR is a registered trademark of Merck & Co., Inc.
For general information and other services for physicians
MerckProductServices is a trademark of Merck & Co., Inc.
Merck OnCall® is a registered trademark of Merck & Co., Inc.
MerckServices is a trademark of Merck & Co., Inc.
